Online inquiry

IVTScrip™ mRNA-Anti-C3&C4, APT070(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3133MR)

This product GTTS-WQ3133MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets C3&C4 gene. The antibody can be applied in Cardiopulmonary bypass (CPB) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000064.4; NM_001002029.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 718; 721
UniProt ID P01024; P0C0L4
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-C3&C4, APT070(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ3133MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12420MR IVTScrip™ mRNA-Anti-IFNG, NI-0501(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA NI-0501
GTTS-WQ9063MR IVTScrip™ mRNA-Anti-IGF1R, IMC-A12(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IMC-A12
GTTS-WQ11898MR IVTScrip™ mRNA-Anti-CCR2, MLN-1202(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MLN-1202
GTTS-WQ8635MR IVTScrip™ mRNA-Anti-AXL, HuMax-AXL-ADC(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA HuMax-AXL-ADC
GTTS-WQ12190MR IVTScrip™ mRNA-Anti-CSF2, MORAb-022(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MORAb-022
GTTS-WQ4779MR IVTScrip™ mRNA-Anti-TNFSF13B, BR3-Fc(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BR3-Fc
GTTS-WQ8020MR IVTScrip™ mRNA-Anti-CD52, GZ-402668(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA GZ-402668
GTTS-WQ5707MR IVTScrip™ mRNA-Anti-CD3E&CEACAM5, CEA TCB(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CEA TCB
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW